Literature DB >> 1371124

Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries.

E R Edelman1, M A Nugent, L T Smith, M J Karnovsky.   

Abstract

Basic fibroblast growth factor (bFGF) is mitogenic for smooth muscle cells (SMC) and angiogenic. We examined the in vivo effects of bFGF in balloon denuded carotid arteries of laboratory rats. bFGF was administered continuously from polymer-based devices at 34 ng/d into the periadventitial space of rat carotid arteries for 2 wk. Intimal hyperplasia was not observed in the absence of injury or with lipopolysaccharide induced endothelial dysfunction. Different degrees of vascular injury produced proportionally more intimal hyperplasia. bFGF increased the intimal hyperplastic response 1.3-fold with severe vascular injury, and 2.4-fold with more mild injury. Increased cell proliferation, not extracellular matrix production, accounted for these effects. Cell density was unchanged for the control and bFGF-treated groups, and the number of proliferating intimal cells at 2 wk rose to an amount equivalent to the increase in mass; 1.9- and 4.0-fold for severe and lesser injury, respectively. The relative ability of heparin to reduce SMC proliferation was not altered by the presence of bFGF.bFGF also induced profound angiogenesis within and surrounding the polymeric releasing device, and in the vasa vasorum immediately around the injured arteries. bFGF's effect on vasa was linearly related to the amount of SMC proliferation within the blood vessel. Thus, the in vivo mitogenic and angiogenic potential of bFGF are coupled, and may be similarly modulated by the products of local injury and/or factors in the vessel wall.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1371124      PMCID: PMC442874          DOI: 10.1172/JCI115607

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

Review 1.  Biological and biochemical properties of fibroblast growth factors. Implications for the pathogenesis of atherosclerosis.

Authors:  M Klagsbrun; E R Edelman
Journal:  Arteriosclerosis       Date:  1989 May-Jun

2.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury.

Authors:  J S Powell; J P Clozel; R K Müller; H Kuhn; F Hefti; M Hosang; H R Baumgartner
Journal:  Science       Date:  1989-07-14       Impact factor: 47.728

3.  Basic fibroblast growth factor induces angiogenesis in vitro.

Authors:  R Montesano; J D Vassalli; A Baird; R Guillemin; L Orci
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

Review 4.  Fibroblast growth factor: structural and biological properties.

Authors:  D Gospodarowicz; G Neufeld; L Schweigerer
Journal:  J Cell Physiol Suppl       Date:  1987

5.  Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor).

Authors:  J A Winkles; R Friesel; W H Burgess; R Howk; T Mehlman; R Weinstein; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

6.  An in vivo model for study of the angiogenic effects of basic fibroblast growth factor.

Authors:  A Hayek; F L Culler; G M Beattie; A D Lopez; P Cuevas; A Baird
Journal:  Biochem Biophys Res Commun       Date:  1987-09-15       Impact factor: 3.575

7.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

8.  Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin.

Authors:  J R Guyton; R D Rosenberg; A W Clowes; M J Karnovsky
Journal:  Circ Res       Date:  1980-05       Impact factor: 17.367

9.  Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form.

Authors:  M Presta; J A Maier; M Rusnati; G Ragnotti
Journal:  J Cell Physiol       Date:  1989-07       Impact factor: 6.384

10.  Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury.

Authors:  L Jonasson; J Holm; G K Hansson
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more
  44 in total

Review 1.  The evolution of endothelial regulatory paradigms in cancer biology and vascular repair.

Authors:  Joseph W Franses; Elazer R Edelman
Journal:  Cancer Res       Date:  2011-12-05       Impact factor: 12.701

Review 2.  Incorporation of heparin into biomaterials.

Authors:  Shelly E Sakiyama-Elbert
Journal:  Acta Biomater       Date:  2013-09-08       Impact factor: 8.947

3.  Adventitia as a target for intravascular local drug delivery.

Authors:  T Y Huehns; P Gonschior; B Höfling
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

4.  Cell-mediated Delivery and Targeted Erosion of Vascular Endothelial Growth Factor-Crosslinked Hydrogels.

Authors:  Sung Hye Kim; Kristi L Kiick
Journal:  Macromol Rapid Commun       Date:  2010-07-08       Impact factor: 5.734

5.  Heparin inhibits the binding of basic fibroblast growth factor to cultured human aortic smooth-muscle cells.

Authors:  F Bono; P Rigon; I Lamarche; P Savi; V Salel; J M Herbert
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

6.  Fibroblast growth factor receptor-1 expression is associated with neointimal formation in vitro.

Authors:  S J Daley; A I Gotlieb
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury.

Authors:  S Villaschi; R F Nicosia
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

8.  Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet-derived growth factor B chain in vascular endothelium.

Authors:  A M Malek; G H Gibbons; V J Dzau; S Izumo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages.

Authors:  E Brogi; J A Winkles; R Underwood; S K Clinton; G F Alberts; P Libby
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 10.  Anti-angiogenic activity of rPAI-1(23) and vasa vasorum regression.

Authors:  Mary Jo Mulligan-Kehoe
Journal:  Trends Cardiovasc Med       Date:  2013-01-11       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.